Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder

Journal of Women's Health and Gender-Based Medicine

Volumn 10, Issue 6, 2001, Pages 561-569

  Freeman, Ellen W ^a   Kroll, Robin ^b   Rapkin, Andrea ^c   Pearlstein, Teri ^d   Brown, Candace ^e   Parsey, Kelly ^f   Zhang, Paul ^g   Patel, Harji ^g   Foegh, Marie ^g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b North Seattle Women's Group   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BUTLER HOSPITAL   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f Berlex Laboratories ^*  (United States)

^g BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BROMOCRIPTINE; DANAZOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTROGEN; GONADORELIN AGONIST; MINERALOCORTICOID ANTAGONIST; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE DERIVATIVE; PYRIDOXINE; SPIRONOLACTONE;

ACNE; ADULT; APPETITE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DYSPHORIA; FEEDING BEHAVIOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MULTICENTER STUDY; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADAPTATION, PSYCHOLOGICAL; ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DEPRESSION; DOUBLE-BLIND METHOD; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; PREMENSTRUAL SYNDROME; TREATMENT OUTCOME; UNITED STATES;

EID: 0034865958     PISSN: 15246094     EISSN: None     Source Type: Journal    
DOI: 10.1089/15246090152543148     Document Type: Article

References (45)

1. Perimenstrual symptoms: Prevalence and risk factors
2. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: Attributable risk and risk factors
3. Menstrual cycle symptom variation in a community sample of women using and not using oral contraceptives
4. Pharmacological management of premenstrual disorder
5. Premenstrual syndrome: Current perspectives on treatment and etiology
6. Premenstrual syndromes: Closing the 20th century chapters
7. From GnRH to SSRIs and beyond: Weighing the options for drug therapy in premenstrual syndrome
8. A comparison of the cycle control and tolerability of two ultralow-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene
9. The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use
10. Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparations
11. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: Placebo-controlled study
12. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol
13. A risk-benefit appraisal of drugs used in the management of premenstrual syndrome
14. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome
15. The treatment of severe premenstrual syndrome with goserelin with and without "add-back" estrogen therapy: A placebo-controlled study
16. Effect of spironolactone on premenstrual syndrome symptoms
17. Premenstrual tension: A placebo-controlled efficacy study with spironolactone and medroxyprogesterone actate
18. Sprionolactone in the treatment of premenstrual tension: A double-blind study of spironolactone versus bendroflumethiazide and placebo
19. The influence of menstrual cycle phase on the relationship between testosterone and aggression
20. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls
21. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: Effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women
22. The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential
23. Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity
24. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: The Calendar of Premenstrual Experiences
25. Measurement properties of a daily symptom diary in patients with premenstrual syndrome
26. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study
27. Fluoxetine in the treatment of premenstrual syndrome
28. Treatment of premenstrual syndrome with fluoxetine: A double-blind, placebo-controlled, crossover study
29. Assessment of depression: The depression inventory
30. Rating scales and checklists for child psychopharmacology
31. Characteristics of placebo responses in medical treatment of premenstrual syndrome
32. The psychopharmacological treatment of nomajor mood disorders
33. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin
34. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome
35. Fluoxetine in the treatment of premenstrual dysphoria
36. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial
37. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review
38. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder
39. Acute tryptophan depletion aggravates premenstrual syndrome
40. Estrogen-serotonin interactions: Implications for affective regulation
41. Premenstrual syndrome, neuroactive steroids and the brain
42. The levels of androgen in serum in female acne patients